RTW Biotech Opportunities Ltd

Overview

RTW Biotech Opportunities Ltd is a London Stock Exchange-listed investment trust focusing on biotechnology investments. The company aims to identify transformative assets with high growth potential across the life sciences sector, applying deep scientific expertise with a long-term investment horizon. It invests in companies developing innovative medical therapies for diseases with limited treatment options. The investment strategy involves full lifecycle investing, supporting scientists and entrepreneurs at any stage where opportunities are identified, from academic programs in need of industry sponsorship to mature publicly traded companies. The company seeks to maximize value realization from transformative products over time, being involved and invested in such companies throughout various stages of their development and delivery to patients. As of 31 January 2026, RTW Biotech Opportunities Ltd reported an ordinary net asset value (NAV) of $772.4 million, with an NAV per share of $2.37 and a market capitalization of $691.9 million. The company has achieved a 127.6% growth in ordinary NAV per share since admission and a 103.9% total shareholder return since admission. Recent developments include the acquisition of RAPT Therapeutics by GSK, with the acquisition price representing a 65% premium to RAPT's closing share price on 19 January 2026. The company is managed by RTW Investments, LP, a seasoned healthcare investment firm.